ChabioTech Administers First Patient Dose in Phase 1 Clinical Trial of Immune Cell Therapy

[Asia Economy Reporter Cho Hyun-ui] Cha Biotech announced on the 6th that it has completed the first patient administration in the Phase 1 clinical trial of the immune cell therapy ‘CBT101’ in South Korea.

The ongoing Phase 1 clinical trial at Bundang Cha Hospital evaluates the safety and tolerability of CBT101 in patients with solid tumors. It aims to determine the maximum tolerated dose and the recommended dose for Phase 2, while also observing the drug’s immune response and its effects on tumor recurrence.

CBT101 is an immune cell therapy manufactured by extracting NK cells, which play a crucial role in innate immunity, from the patient’s own blood and expanding them ex vivo. Cha Biotech explained, “Our proprietary cell culture technology increases the proliferation capacity of NK cells by approximately 2000 times and enhances NK cell activity from about 5-10% to 90%, significantly strengthening the anticancer effect.”

Previously, in September, CBT101 was designated as an orphan drug for malignant glioma by the U.S. Food and Drug Administration (FDA). Treatments designated as orphan drugs receive various benefits such as tax reductions and seven years of market exclusivity after approval, which can greatly shorten the time from clinical trials to commercialization. Cha Biotech plans to accelerate its entry into the global market, including the U.S., through rapid clinical progress and product commercialization.

Oh Sang-hoon, CEO of Cha Biotech, stated, “CBT101 has competitiveness through research targeting various solid tumors and related technology patents. We will do our best to accelerate commercialization through swift clinical progress.”

This content was produced with the assistance of AI translation services.